5月27日，丹诺医药-B盘中上涨5.94%，报249.6港元，成交额923.75万港元。该股于5月22日以75.7港元发行价登陆港交所，上市首日即大涨逾178%，本次异动系上市后延续强势表现。
消息面上，丹诺医药公开发售阶段获9015.11倍认购，为今年港股主板超购倍数第二高新股。公司核心产品利福特尼唑是全球首个针对幽门螺杆菌感染的新分子实体候选药物，已于去年8月向国家药监局提交新药上市申请，预计今年底获批。中国幽门螺杆菌感染率约44%，涉及超6亿患者，市场空间广阔。此外，另一核心产品利福喹酮注射剂正推进全球III期临床，为目前唯一处于后期临床开发的人工关节感染小分子候选药物。
丹诺医药（苏州）股份有限公司是一家主要从事发现、开发创新药产品的中国公司，专注于细菌感染和代谢相关疾病领域。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.